# 723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover

> **NCT00972504** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 54 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** GSK835726 10mg
- **DRUG:** GSK1004723 1000mcg
- **DRUG:** Cetirizine 10mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00972504
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-01
- **Primary completion:** 2009-08-01
- **Final completion:** 2009-08-14
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00972504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00972504, "723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00972504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*